There were "emerging concerns" about the use of the drug, authorities said.
London (Reuters):
Britain's drug regulator on Tuesday instructed scientists trialling the use of malaria drug hydroxychloroquine for the treatment or prevention of COVID-19 to suspend the recruitment of participants.
The Medicines and Healthcare products Regulatory Agency (MHRA) said it was following "emerging concerns" about the use of the drug, and also cited a UK trial which found no meaningful mortality benefit in patients hospitalised with COVID-19.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
Track Latest News Live on NDTV.com and get news updates from India and around the world
